ERBB2 and neoplasm: Ojesina et al. (2014) reported 115 cervical carcinoma–normal paired samples' whole-exome sequence analysis, 79 cases' transcriptome sequence, and 14 tumor–normal pairs' whole genome sequence and detected significantly recurrent somatic mutations in the mitogen-activated protein kinase 1 (MAPK1) gene among squamous cell cervical cancers and provided evidence of potential ERBB2 (also means HER2/neu) activation by somatic mutation, amplification, and HPV integration to combat cervical carcinoma.